Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the central nervous system (CNS).
Our first-generation compound, GLYX-13, is in development as adjunctive therapy for patients with difficult-to-treat depression. GLYX-13 has shown rapid-acting and robust antidepressant activity in Phase 2 clinical studies and has been well tolerated with none of the psychotomimetic side effects that limit other drugs and mechanisms targeting the NMDA receptor. Naurex’s second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development for the treatment of major depressive disorder.
These lead programs stem from the company’s proprietary platform for discovering compounds that work through a novel mechanism, selectively modulating subtypes of the NMDA receptor to affect pathways involved with neuroplasticity. This mechanism has therapeutic potential in a number of CNS indications with high unmet medical needs.